Integra LifeSciences (IART) Q2 2025

Q1 2026 Q4 2025 Q3 2025 Q2 2025

Earnings

Integra LifeSciences delivered a stronger-than-expected second quarter, posting adjusted EPS of $0.45 against a consensus estimate of $0.43 for a 4.38% beat, while revenue of $415.61 million topped estimates by 5.20%, even as reported sales slipped 0… Read more Integra LifeSciences delivered a stronger-than-expected second quarter, posting adjusted EPS of $0.45 against a consensus estimate of $0.43 for a 4.38% beat, while revenue of $415.61 million topped estimates by 5.20%, even as reported sales slipped 0.6% year over year amid ongoing quality remediation headwinds. The headline numbers, however, were overshadowed by a $511.37 million goodwill impairment charge tied to the company's depressed stock price, which drove a GAAP net loss of $484.07 million, or $6.31 per diluted share, compared to a loss of $0.16 a year ago. Adjusted gross margin contracted to 60.7% from 65.2%, reflecting the continued cost burden of the Boston facility transition and EU regulatory compliance. Despite the turbulence, Codman Specialty Surgical grew 0.7% to $303.96 million, and management noted mid-single-digit underlying growth when stripping out shipping hold impacts. Shares have significantly underperformed the broader market year-to-date, though the company updated full-year revenue guidance to $1.66 billion to $1.68 billion and reaffirmed adjusted EPS of $2.19 to $2.29, while projecting a meaningful organic growth acceleration in Q3.